Hybio Pharmaceutical Co., Ltd. (300199.SZ) SHZ

24.44

-0.49(-1.97%)

Updated at September 08 03:07PM

Currency In CNY

Hybio Pharmaceutical Co., Ltd.

Address

Hanyu Biological Park, No. 37

Shenzhen, 518057

China

Phone

86 755 2658 8000

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

895

First IPO Date

April 07, 2011

Key Executives

NameTitlePayYear Born
Ms. Di YangVice President, Secretary & Director01985
Mr. Honghong TuVice President, Chief Financial Officer & Accounting Supervisor01976
Ms. Min ZhangVice President01980
Mr. Heng QuanVice President of Human Resource & Administration Department0N/A
Mr. Yu LiuVice President of Marketing0N/A
Ms. Yu PinxiangExecutive President & Director01973
Mr. Zhaohui ZengVice President01974

Description

Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.